Havana, November 19 (RHC)-- Cuba's Industrial Property Office has presented the Cuban advanced lung cancer vaccine, developed by the Havana-based Molecular Immunology Center, with the Creativity and Technical Innovation Award 2015.
Registered in Cuba since 2012, the product called Vaxira, has a very favorable impact of the patients' survival rate and quality of life, while no side-effects have been reported.
Vaxira is now registered in 17 countries. Studies are currently underway to assess its impact on patients suffering from breast and ovarian cancers.
